clinical trial · NCT07400965
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Demodex BlepharitisGLK-321 low dose BIDGLK-321 mid dose BIDGLK-321 high dose BIDGLK-321 high dose QDPlacebo BID
brief summary
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
started
Dec 5, 2025
primary completion
Sep 1, 2026
completion
Nov 1, 2026
last updated
Feb 27, 2026
official title
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol